phrykt

Actuate Therapeutics, Inc. (ACTU): who owns it and who trades it

As of Nov 16, 2026, ACTU insiders reported 1 open-market sale worth $1.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Todd S Thomson (Director), with $1.6M. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Actuate Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ACTU

64 funds and institutions reported ACTU shares worth $20.7M at the end of Q2 2026, about 57% of the company. The largest holder is BIOS Capital Management, LP with 42.4%.

Funds and institutions (13F) 57%Everyone else 43%

10 largest owners, by share of the company

BIOS Capital Management, LP42.4%
Voss Capital, LP7.3%
Vanguard Capital Management LLC1.7%
AQR Capital Management LLC0.5%
Geode Capital Management, LLC0.5%
Texas Capital Bank Wealth Management Services Inc0.4%
Palogic Value Management, L.P.0.4%
Millennium Management LLC0.4%
BlackRock, Inc.0.4%
ABS Investment Management LLC0.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BIOS Capital Management, LP10.05M42.39%$15.4MNo change
Voss Capital, LP1.73M7.28%$2.6MNo change
Vanguard Capital Management LLC393,4331.66%$602K-2%
AQR Capital Management LLC127,4930.54%$195K+370%
Geode Capital Management, LLC112,5540.47%$172K-51%
Texas Capital Bank Wealth Management Services Inc102,6120.43%$157K+8%
Palogic Value Management, L.P.100,0000.42%$153KNo change
Millennium Management LLC96,6840.41%$148KNew
BlackRock, Inc.90,0350.38%$138K-79%
ABS Investment Management LLC73,1860.31%$112KNew
ABS Direct Equity Fund LLC73,1860.31%$112K+46%
Vanguard Fiduciary Trust Co54,4970.23%$83.4K-13%
Rock Creek Group LLC39,2630.17%$60.1KNo change
Jane Street Group, LLC39,1320.17%$59.9KNew
HighTower Advisors, LLC36,4610.15%$55.8KNew
Goldman Sachs Group Inc35,4980.15%$54.3K+186%
Sfmg, LLC33,0000.14%$50.5KNo change
Susquehanna International Group, LLP28,1820.12%$43.1KNew
Bridgeway Capital Management, LLC23,4820.10%$35.9K-24%
State Street Corp21,8500.09%$33.4K-67%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ACTU insiders reported $0 of open-market purchases and $1.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.6M
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jan 5, 2026
Filed Jan 7, 2026

Purchases and sales by month

$1.6M$1.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jan 5, 2026Todd S Thomson +1DirectorSale280,000$5.80$1.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Todd S ThomsonDirector, 10% owner–$1.6MJan 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ACTU short interest

Moderate short interest. 5.4% of ACTU shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went up 47%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.30M ACTU shares were sold short, 5.4% of the shares outstanding, down 30.5% from the report before. At the average daily volume of 611,422 shares, buying them all back would take about 2.1 trading days (days to cover).

Shares short, % of all shares

5.41%May 15Oct 308.66%

Days to cover

2.1May 15Oct 3010.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.30M5.41%-30%611,4222.1
Oct 15, 20261.87M7.78%+40%396,8924.7
Sep 30, 20261.33M5.54%+21%236,9575.6
Sep 15, 20261.10M4.57%-6%341,5393.2
Aug 31, 20261.17M4.88%+68%612,1451.9
Aug 14, 2026695,9712.90%+55%193,0803.6
Jul 31, 2026450,1801.90%-40%155,0922.9
Jul 15, 2026754,7543.18%+10%726,0091.0
Jun 30, 2026687,1022.90%-25%178,9713.8
Jun 15, 2026915,4283.86%-1%206,0044.4
May 29, 2026920,6303.88%+4%102,7439.0
May 15, 2026883,2163.73%-7%128,8146.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Actuate Therapeutics company events

Actuate Therapeutics filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Oct 30, 2026.

  1. Oct 30, 2026ListingNotice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. Filing
  2. Oct 28, 2026AgreementActuate Therapeutics, Inc., a Delaware corporation, entered into an Underwriting Agreement with Newbridge Securities Corporation, acting as sole book-running manager, relating to the issuance and sale of 30,985,900 shares of the Company’s common stock, par value $0.000001 per share, and warrants to… Filing
  3. Jul 17, 2026ListingNotice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. Filing
  4. May 22, 2026VoteReported shareholder vote results. Filing
  5. May 11, 2026AnnouncementShared information with investors. Filing
  6. May 6, 2026LeadershipThe Board of Directors of Actuate Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board. Filing
  7. Jan 12, 2026AnnouncementShared information with investors. Filing
  8. Nov 28, 2025AgreementActuate Therapeutics, Inc. entered into an At the Market Issuance Sales Agreement with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, $0.000001 par value per share, to or… Filing
  9. Nov 21, 2025AnnouncementMade another announcement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Actuate Therapeutics financials

Famous investors that hold ACTU

1 of the 50 well-known investors we track reported holding ACTU in their latest 13F filing. The largest position is Israel Englander's, worth $70.3K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202690,195$70.3K0.0%-7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ACTU in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Hexstone Capital LLC13G7.7%
Oct 30, 2026Hexstone Capital LLC13G7.7%

Questions about Actuate Therapeutics, Inc. (ACTU) stock

Who owns the most ACTU stock?

The largest reported owner of Actuate Therapeutics, Inc. (ACTU) is BIOS Capital Management, LP, with 42.4% of the company. In total, 64 funds and institutions reported holding ACTU at the end of Q2 2026, together about 57% of the shares. See the largest owners.

Are ACTU insiders buying or selling?

In the last 12 months, ACTU insiders reported no open-market purchases and 1 sale worth $1.6M. The latest trade was on Jan 5, 2026. See every trade.

What is the short interest in ACTU?

As of Oct 30, 2026, 1.30M ACTU shares were sold short, 5.4% of the shares outstanding, down 30.5% from the report before. At the average daily volume of 611,422 shares, buying them all back would take about 2.1 trading days (days to cover). See the history.

Which famous investors hold ACTU?

1 of the 50 well-known investors we track reported ACTU in their latest 13F filing, including Israel Englander. The largest position is worth $70.3K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.